top of page
div(1).png

A distinctive
pharmaceutical company

Founded in Barcelona in 2003, Galenicum is a global pharmaceutical company dedicated to developing, manufacturing, and commercializing high-quality medicines.


What makes us distinctive is our culture: we are entrepreneurial, fast-moving and build real partnerships on trust. Powered by scientific rigor and ownership on every step of the value chain, we embrace challenges as we expand into increasingly complex pharmaceutical products.


Driven by a mission to improve the quality and affordability of healthcare, Galenicum serves pharmaceutical partners, health systems, and patients across more than 70 countries worldwide.

A Broad Portfolio

Our

Business Ecosystem

Gal_ecosystem-04.jpg

B2C

We develop and in-license innovative dermatological products marketed under our own brand ‘Galenicum Derma’ in Spain, with expanding reach in Latin America and globally.                                               

More Derma
Gal_ecosystem-03.jpg

B2C

We commercialize bioequivalent medicines under our own brand 'Vitae' across Latin America, the Middle East, and Africa. Our portfolio includes both group-developed and in-licensed pharmaceutical products.

More Vitae
Gal_ecosystem-02.jpg

B2B

We manufacture high-quality pharmaceutical products in various formats and technologies at our own plant in Spain, with a capacity of over 100 million packs per year and global reach.                                      

More SAG
Gal_ecosystem-01.jpg

B2B

We partner with pharmaceutical companies worldwide to source APIs and to research & develop, license, and supply FDFs and complex FDFs.

​

More Axium
div(2).png

Our

Footprint

From our headquarters in Barcelona and manufacturing site in Madrid, we manage operations in more than 70 countries, with local teams in Spain, Chile, Perú, Colombia, Ecuador, India, and the United Arab Emirates.

Get in Touch
Gal_Planisferio.jpg

Do business with us

Get In Touch

Be part of the team

Apply Now

Our

Numbers

2025

Consolidated Revenues

303M€

Countries

73

CAPEX

47M€

Marketing Authrorisation Granted

131

Employees

+900

Active R&D Projects per Year

+30

bottom of page